Subdermal mini-pump with exenatide superior to sitagliptin in reducing HbA1c

NEW ORLEANS – The second trial involving a sub-dermal matchstick-size osmotic mini-pump that releases exenatide over 6 months in people who have poorly controlled type 2 diabetes achieved superior...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news